Eli Lilly vs. Novo Nordisk: One GLP-1 Profit Pool, a 3.6x Valuation Gap

Zacks's latest analyst-blog roundup puts four companies in one sentence: Eli Lilly, Palo Alto Networks, Texas Instruments, and Stratus Properties. A hedge fund, a chipmaker, a firewall vendor, and a Texas real-estate developer. They share an exchange and a press release, and nothing else. Bundled that way, "buy the list" is meaningless — it is the famous-names trap, and the trap is the story.

Strip it down and one genuine duel is hiding in the lead. It is not between any two of the four names in the release. It is between Lilly, the anchor of the bunch, and the rival it is currently beating: Novo Nordisk.

The card

Same bell, same clock, one question: can Lilly's faster growth repay a price that is roughly 3.6 times Novo's, or does Novo's cheap multiple make it the better total-return path?

• Contestants: Eli Lilly (LLY) vs. Novo Nordisk (NVO), both US-listed ADRs, both in the same GICS sub-industry (Chemical Pharmaceuticals), both fighting over the same GLP-1 obesity-and-diabetes profit pool.
• Starting line: both normalized to 100 paper points at Tuesday, September 9's close — Lilly at about $1,124, Novo at $45.16 — in US dollars on the NYSE calendar.
• Finish: twelve months out, September 9, 2027.
• Score: total return, dividends reinvested, measured from the closing print. No substitutions, no rebalancing.
• Hidden exposures on the card: Novo is a Danish company whose ADR carries currency risk, and its US revenues have been shrinking. Both companies are spending heavily on new capacity.
• Editorial odds: Lilly opens a modest 55/45 favorite. That is momentum and pipeline, not a promise, and it could swing on the mechanism board below.

Why the two belong together

These are not an incumbent and a stranger. They are the two companies that own the weight-loss revolution, and their unit economics are startlingly close. Lilly's gross margin is about 82.8% and its operating margin about 47.9%; Novo runs an 81.9% gross margin and a 45.3% operating margin. Return on invested capital is 40% versus 35%. Dollar for dollar, these businesses make money the same way.

The disagreement is entirely about expectations. Lilly trades at roughly 39.6 times trailing earnings and about 63 times forward earnings, on a $1.06 trillion market cap. Novo trades at about 11 times forward earnings on a $197 billion cap with a dividend yield near 3%. The market has already decided, in the price, that Lilly keeps winning and Novo keeps losing.

The split that decides it

On August 5, the two reported and the market hung a sign on each. Lilly's second-quarter revenue jumped 48% to nearly $23 billion, beating the consensus of about $20.6 billion, and management raised its full-year revenue forecast to $85–87 billion. Its injectable GLP-1 franchise — Mounjaro and Zepbound, built on tirzepatide — is described as the world's best-selling drug, and Lilly's stock now sits above a trillion-dollar valuation.

Novo headed the other way. Its experimental next-gen injectable CagriSema failed to control blood sugar as well as tirzepatide in a head-to-head trial, its oral Wegovy pill sales missed analyst estimates, and its projected US sales are now flat to down as much as 6% at constant currencies. Its shares fell about 6% that day and are down more than 20% over the trailing year. That is the price move; the mechanism beneath it is that Novo lost its shot at the next chapter of shots and is now leaning on a pill.

The pill is the twist that keeps this from being a coronation. 2026 is the year oral GLP-1s go mainstream, and here Novo moved first: its once-daily Wegovy pill is already on the market, while Lilly's oral candidate (orforglipron) still awaits US approval. Wall Street forecasts pills could be worth close to $22 billion of the global weight-loss market by 2030. Novo's pill also looks like the more potent one on the data — roughly 16.6% average weight loss versus about 12.4% for Lilly's — though it demands a fiddlier dosing ritual, and Goldman projects Lilly still takes a larger pill-market share on convenience.

Two scoreboards, one honest call

Split the scoreboards, because they point in different directions.

The price scoreboard favors Lilly: momentum, a raised guide, the best-selling drug on earth. The mechanism board is genuinely split. Lilly couples exceptional revenue growth — about 50% year over year, against Novo's roughly 12% — with a forward earnings multiple near 63 times, a thin 0.6% dividend, and a free-cash-flow margin (about 18.5%) squeezed by the billions it is pouring into new factories. Novo offers 11 times forward earnings, a ~3% dividend, a real earnings yield if the contraction stops — but a shrinking US business and a broken pivotal pipeline bet.

So the asymmetry is the reverse of normal caution. Lilly does not have to fail to lose; it merely has to hit its targets and confirm a multiple that already promises years of flawless execution. Novo does not have to win to pay; it mostly has to stop losing. That is why the odds are close despite the earnings gap.

At the bell, momentum plus pipeline depth keeps Lilly a slight favorite. But this is a debate about which expectation is wrong, not about which company is better — both run 80%-plus gross margins. The design lesson, and the thing Zacks's four-name list obscures: when two businesses make money identically and the market prices one at 3.6 times the other, the race rewards whichever expectation breaks first. Check back at the first checkpoint — the next earnings and the orforglipron approval decision — and see whether Novo's near-3% yield and 11 times multiple buy time for the record to catch up to Lilly's price.